Reported Friday, MannKind's Afrezza Data At ADA Highlight Pediatric Safety, Gestational Diabetes Efficacy And AID System Compatibility Following May 2026 FDA Pediatric Approval
Benzinga · 06/08 07:44
Share
Listen to the news
- Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes
- New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction
- Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms
- Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved